Full text is available at the source.
Abstract
Psychedelic drug therapy is being explored for its potential in treating mental health conditions, including depression, PTSD, and anxiety.
- Psychedelic treatment operates differently from conventional psychiatric methods.
- Key substances examined include psilocybin, MDMA, mescaline, ketamine, and LSD.
- Psychedelics are classified as Schedule I substances in the US, indicating potential for misuse.
- The USFDA is involved in monitoring and expediting the evaluation of psychedelics.
- Recent FDA guidance supports the safe development of psychedelics for human use.
- Limited distribution of products like Spravato nasal spray is linked to safety concerns.
Simplified